公开(公告)号：EP4036087A1

公开(公告)日：2022-08-03

申请号：EP20870084.9

申请日：2020-09-24

申请人： Shenzhen Salubris Pharmaceuticals Co. Ltd

发明人： WU, Junjun ,  LU, Yinsuo ,  XIAO, Ying ,  HONG, Zexin ,  WU, Jianli ,  XING, Wei

IPC分类号： C07D401/14 ,  C07D401/12 ,  C07D401/10 ,  A61K31/501 ,  A61K31/495 ,  A61K31/395 ,  A61P7/02 ,  A61P9/10

摘要： Provided in the present invention is a series of selective Factor XIa (FXIa) inhibitors, relating to the technical field of chemical drugs. The present invention also relates to pharmaceutical compositions containing said compounds and a use of said compounds in drugs for the treatment of diseases such as thromboembolism.

公开(公告)号：EP4219463A1

公开(公告)日：2023-08-02

申请号：EP22855515.7

申请日：2022-08-12

申请人： Shenzhen Salubris Pharmaceuticals Co., Ltd.

发明人： WU, Junjun ,  LU, Yinsuo ,  XIAO, Ying ,  HONG, Zexin ,  WANG, Liulin ,  SONG, Zenan

IPC分类号： C07D401/14 ,  A61K31/33 ,  A61P29/00

摘要： This application belongs to the technical field of chemical drugs, and relates to a compound shown in a general formula (I), or racemate thereof, or an isomer thereof, or a pharmaceutically acceptable salt thereof,

which, as a p38/MK2 inhibitor, may inhibit the generation of cytokines TNFα and is used for treating diseases such as arthritis.